ArticleTranslational cancer research2025
Immune-related long noncoding RNAs in predicting the prognosis and immune landscape of intrahepatic cholangiocarcinoma: a bioinformatics analysis with experimental verification.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between primary tumor resection and survival in metastatic intrahepatic cholangiocarcinoma: a retrospective cohort study based on the SEER database.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long noncoding RNAs (lncRNAs) are extensively involved in tumor immunity. The aim of this study was to construct an immune-related lncRNA (irlncRNA) signature for predicting the prognosis and immune landscape of intrahepatic cholangiocarcinoma (ICC) and to clarify the related mechanisms. Methods: Transcriptome and clinicopathological data were downloaded from The Cancer Genome Atlas (TCGA) database. The immune-related genes (IRGs) were collected from the ImmPort database. Coexpression analysis was used to identify the key lncRNAs related with IRGs. Differentially expressed and cox regression analysis was used to screen the differentially expressed and survival-related irlncRNAs, whose expression was measured in ICC and compared with that of normal controls via quantitative real-time polymerase chain reaction (qRT-PCR). Subsequently, an optimal model was established to differentiate patients into high- and low- risk groups. The association of this signature with overall survival (OS) was evaluated via Kaplan-Meier (KM) survival analysis. Principal component analysis (PCA) was applied to determine the capability of risk model to differentiate patients. Results: A total of six irlncRNAs (APCDD1L-DT, WAC-AS1, LINC01615, AL391056.1, AC090114.2, and LINC01711) were identified as independently predictive indicators and were then validated via qRT-PCR. A prognostic signature was then constructed via multivariate Cox regression analyses. This signature was found to be an independent prognostic indicator of OS compared with the other clinicopathologic characteristics examined. The KM survival analysis demonstrated the good predictive capability of the signature, and the PCA results revealed good risk discrimination. The tumor-infiltrating immune cells, chemotherapeutics efficacy, and expression of immune checkpoint genes were also evaluated between the high- and low-risk groups. Conclusions: The prognostic signature consisting of irlncRNAs could predict the prognosis and immune landscape of patients with ICC and may provide a novel perspective for the individualized intervention in ICC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.